SLXN

Silexion Therapeutics Corp Ordinary Shares

0.11

USD

-0.01

-12.11%

Nov 10, 15:51 UTC -5

Closed

After-Market

0.11

0.00

+0.09%

Silexion Therapeutics Corp Ordinary Shares (SLXN) Earnings

SLXN Earnings Reports

Positive Surprise Ratio

SLXN beat 3 of 8 last estimates.

38%

Next Report

Date of Next Report

Estimate for Q-- -- (Revenue/ EPS)

Implied change from Q2 26 (Revenue/ EPS)

Implied change from Q-- -- (Revenue/ EPS)

Silexion Therapeutics Corp Ordinary Shares earnings per share and revenue

On Aug 14, 2026, SLXN reported earnings of -5.17 USD per share (EPS) for Q2 26, missing the estimate of -2.16 USD, resulting in a -139.09% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a -8.65% price change (close before vs. close after earnings).

Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

CalciMedica, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$1.30

Actual

-$0.72

Surprise

+44.64%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

FAQ

What were Silexion Therapeutics Corp Ordinary Shares's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Silexion Therapeutics Corp Ordinary Shares reported EPS of -$5.17, missing estimates by -139.09%, and revenue of --, -- -- expectations.

How did the market react to Silexion Therapeutics Corp Ordinary Shares's Q2 2026 earnings?

The stock price moved down -8.65%, changed from $0.46 before the earnings release to $0.42 the day after.

When is Silexion Therapeutics Corp Ordinary Shares expected to report next?

The next earning report is scheduled for --.

What are the forecasts for Silexion Therapeutics Corp Ordinary Shares's next earnings report?

Based on -- analysts, Silexion Therapeutics Corp Ordinary Shares is expected to report EPS of -- and revenue of -- for Q-- --.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.